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ABSTRACT
Introduction: Secukinumab, a fully human
monoclonal antibody that directly inhibits
interleukin-17A, has demonstrated robust effi-
cacy in the treatment of moderate to severe
psoriasis (PsO), psoriatic arthritis (PsA) and
ankylosing spondylitis (AS), with a rapid onset
of action, sustained long-term clinical responses
and a consistently favourable safety profile
across phase 3 trials. Here, we report the clinical
data at enrolment from SERENA, designed to
investigate the real-world use of secukinumab
across all three indications.
Methods: SERENA is an ongoing, longitudinal,
observational study conducted at 438 sites
across Europe in patients with moderate to
severe plaque PsO, active PsA or active AS.
Patients should have received at least 16 weeks
of secukinumab treatment before enrolment in
the study.
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Results: Overall 2800 patients were included in
the safety set; patients with PsA (N = 541) were
older than patients with PsO (N = 1799) and
patients with AS (N = 460); patients with PsO
had a higher mean body weight than patients
with PsA and patients with AS; and patients
with PsO and patients with AS were predomi-
nantly male. Time since diagnosis was longer in
patients with PsO compared with patients with
PsA and patients with AS, and about 40% of
patients were either current or former smokers.
The proportion of obese patients (body mass
index C 30 kg/m2) was similar across indica-
tions. Patients were treated with secukinumab
for a mean duration of 1 year prior to enrolment
(range 0.89–1.04). The percentages of patients
with prior biologics exposure were 31.5% PsO,
59.7% PsA and 55% AS. The percentages of
patients prescribed secukinumab monotherapy
were 75% (n = 1349) in PsO, 48.2% (n = 261) in
PsA and 48.9% (n = 225) in AS groups.
Conclusion: Baseline demographics of the
study population are consistent with existing
literature. This large observational study across
all secukinumab indications will provide valu-
able information on the long-term effectiveness
and safety of secukinumab in the real-world
setting.
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Key Summary Points
Why carry out this study?
Although secukinumab has demonstrated
robust efficacy in the treatment of moderate
to severe psoriasis (PsO), psoriatic arthritis
(PsA) and ankylosing spondylitis (AS), with
a rapid onset of action, sustained long-term
clinical responses, and a consistently
favourable safety profile across numerous
phase 3 trials there is still a need to
investigate the use of secukinumab beyond
the tightly controlled setting of clinical
trials.
There is limited real-world evidence on
long-term retention and efficacy of
secukinumab in patients with moderate to
severe plaque PsO, PsA or AS.
What was learned from the study?
The population recruited into SERENA
reflects that of interventional trials with
secukinumab. However, SERENA patients
are predominantly biologic experienced
and have received multiple biologics,
mostly tumour necrosis factor (TNF)
inhibitors.
This large observational study across all,
currently approved, secukinumab
indications will provide valuable
information on the long-term retention,
effectiveness and safety of secukinumab in
the real-world setting.
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INTRODUCTION
Psoriasis (PsO), psoriatic arthritis (PsA) and
ankylosing spondylitis (AS) are chronic
immune-mediated inflammatory diseases [1].
The pathogenesis of these diseases is a complex
interplay between environmental, genetic and
immune triggers leading to dysregulation of the
immune response [2–5]. These diseases have a
profound impact on patients’ health-related
quality of life (HR-QoL) and are associated with
many comorbidities [6–15].
PsO typically manifests as plaques that occur
most commonly on the elbows and knees, but
can affect any area including palms, soles, nails,
scalp and genitals [16–20]. PsO has a reported
prevalence of between 1.3% and 8.5% in the
adult population of European countries [21].
The proportion of patients with PsO suffering
from PsA has been reported to be 19.7–29%
[22, 23]. A 90% improvement from baseline
Psoriasis Area and Severity Index (PASI) score is
now defined as the threshold of treatment suc-
cess as per the European Medicines Agency and
a ‘‘measure of optimal response’’ by the Ameri-
can Academy of Dermatology [24, 25]. There is
emerging interest in the evaluation of reduction
of absolute PASI score as a better indicator of
therapeutic response and the higher clinical
relevance of the remaining absolute PASI score
as therapeutic target (i.e. PASI score 0–1, B 2,
B 3 and B 5) [26].
Spondyloarthritis (SpA) is an umbrella term
for inflammatory diseases with axial and/or
peripheral manifestations that involve joints,
entheses and extra-articular structures includ-
ing the eyes, skin and gastrointestinal system
[5, 27]. Both PsA and AS are part of the SpA
spectrum of diseases which share genetic, clin-
ical, radiological and therapeutic characteris-
tics, classified according to the Assessment of
Spondyloarthritis International Society (ASAS)
and the Classification of Psoriatic Arthritis
(CASPAR) classification criteria [27–29]. PsA is
characterised by peripheral joint disease,
enthesitis and dactylitis [30, 31]. AS is an
inflammatory disease primarily affecting the
axial skeleton, which may lead to spinal fusion,
deformity and disability. In patients with AS,
extra-articular manifestations (EAMs) such as
psoriasis, acute anterior uveitis and inflamma-
tory bowel disease may be present [32, 33].
Comorbidities include cardiovascular, pul-
monary, renal and neurological involvement
[34, 35]. Prevalence of SpA has been estimated
as 1.4% in the European population, with a
comparable proportion of patients affected by
AS and PsA, and is expected to rise with
increased awareness of SpA and advances in
diagnostic techniques and screening [36].
Interleukin-17A (IL-17A) is a key cytokine in
the pathogenesis of PsO and SpA, driving
inflammation, enthesitis and structural dam-
age. IL-17A produced by Th17 cells, mast cells
and leukocytes drives tissue inflammation, ker-
atinocyte activation and release of psoriasis-as-
sociated molecules [37–41]. The IL-17A
signalling pathway is critical to bone erosion in
PsA and bone fusion in AS [38, 42–45]. Secuk-
inumab, a fully human immunoglobulin G1-
kappa monoclonal antibody that directly inhi-
bits interleukin-17A, has demonstrated robust
efficacy in the treatment of moderate to severe
PsO, PsA and AS, with a rapid onset of action,
sustained long-term clinical responses and a
consistently favourable safety profile across
phase 3 trials [46–48].
In SCULPTURE and ERASURE/FIXTURE
studies, PASI 75/90/100 responses with secuk-
inumab 300 mg were sustained from year 1 to 5
[49, 50]. In FUTURE 2, American College of
Rheumatology response criteria (ACR) 20/50
responses in 300 mg and 150 mg dose groups at
year 1 were sustained or further improved at
year 4. Secukinumab also showed sustained
improvement in PASI 75/90 responses, dactyli-
tis and enthesitis [51]. In MEASURE 2, ASAS
20/40 responses at year 1 were sustained at
year 4 with 150 mg dose [52]. Randomised
controlled trials (RCTs) are the ‘gold standard’
for evaluating the efficacy and safety of new
therapeutic molecules in a highly selective
population in tightly controlled settings
because this strategy reduces confounding fac-
tors. This approach however does not guarantee
that the treatment in everyday clinical practice
will lead to the same results. In the real world,
physicians may deal with more advanced con-
ditions, multiple comorbidities and patients
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who may not be eligible for RCTs or for whom
treatment options have been exhausted. Treat-
ment adherence and persistence in real-world
patient populations can also be a challenge
[53–55].
Secukinumab was approved for the treat-
ment of moderate to severe PsO, PsA and AS in
2015 in the European Union [56]. During the
past 4 years real-world data on secukinumab use
has been gathered in numerous non-interven-
tional trials [57–59], registries [60–62] and dur-
ing the routine collection of post-marketing
safety information. Nevertheless, there is still a
need for an observational study that collects
and analyses the outcomes associated with
underlying disease and its comorbidities, par-
ticularly in terms of assessing long-term reten-
tion, sustainability of effectiveness, long-term
safety, treatment patterns over time and impact
on HR-QoL of secukinumab treatment in
patients with moderate to severe plaque PsO,
PsA and AS.
SERENA is a non-interventional study with
an observational period of up to 5 years
designed to investigate the real-world long-term
use of secukinumab in patients with moderate
to severe PsO, PsA or AS. We report the baseline
clinical data from the overall study population
collected at the time point of enrolment into
the study.
METHODS
Study Design
SERENA (CAIN457A3403) is an ongoing, longi-
tudinal, non-interventional study with
prospective and retrospective collection of pri-
mary data on the retention, safety and effec-
tiveness of secukinumab in patients with
moderate to severe chronic plaque-type PsO,
active PsA or active AS (Fig. 1). The SERENA
study prospectively collects real-world data in
patients who have previously received secuk-
inumab for at least 16 weeks, providing valuable
insights into its long-term effectiveness and
tolerability in clinical practice. Published data
suggests that clinical responses to secukinumab
are usually achieved within 16 weeks
[46, 47, 63, 64] . Patients will participate in the
study for a maximum of 5 years (60 months).
Visits are documented every 6 months after
enrolment. The study will end either when all
enrolled patients (across indications) complete
at least 2 years of follow-up, unless they choose
Fig. 1 Study design. Start of treatment/therapy refers to the period when patients received first dose of secukinumab. Study
enrolment refers to inclusion of patients in the SERENA study (start of observation; baseline visit)
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to exit the study, or when the 5-year visit has
been documented for approximately 1000
patients. The end of study will be determined by
the later of these three time points, i.e. which-
ever occurs last. Individual patients exit the
study if they discontinue secukinumab. All
patients provided written informed consent
before enrolling into the study. The study pro-
tocol was approved by the institutional review
board of each participating centre (Supplemen-
tary Material). The trial was conducted in
accordance with the Declaration of Helsinki and
Good Clinical Practice (GCP) and in compliance
with all federal, local or regional requirements.
Patients
Inclusion Criteria
Adult patients with a diagnosis (assessed by the
treating physician) of active moderate to severe
plaque PsO, active PsA or active AS who are
prescribed secukinumab according to the
approved product information were included in
the study. Patients should have received at least
16 weeks of commercial secukinumab treat-
ment before registration in the study. For
patients in Germany diagnosed as having active
moderate to severe plaque PsO, a PASI assess-
ment on the day of or up to 1 week prior to
initial secukinumab treatment was mandatory.
The decision for treatment with secukinumab
had to be made regardless of this non-inter-
ventional study.
Exclusion Criteria
Patients were excluded from the study if they
had any medical or psychological condition in
the treating physician’s opinion which may
prevent the patient from study participation for
the initial 2 years; participated in parallel in an
interventional clinical trial or Novartis-spon-
sored non-interventional study generating pri-
mary data for secukinumab; were within the
safety follow-up phase of a previous interven-
tional or non-interventional trial using secuk-
inumab as drug of interest or comparator.
Initially, patients who received secukinumab as
an investigational medical product during a
secukinumab interventional trial any time in
the past were allowed to be included into the
SERENA study. After an amendment, inclusion
of these patients was no longer permitted. The
discontinuation of secukinumab treatment after
inclusion into the study resulted in termination
of observation within the study; intermediate
breaks were allowed.
Objectives
The primary objective of the SERENA study is to
assess the long-term retention of secukinumab
treatment in routine clinical practice for the
treatment of moderate to severe plaque-type
PsO, active PsA and active AS, and to identify
factors affecting the retention of secukinumab
treatment for the overall study population.
Collected Data
Patients enrolled to SERENA were treated
according to the local label and data was col-
lected as available in clinical routine. Data on
primary and additional outcome variables were
collected prospectively. Since patients included
in the study were pre-treated with secuk-
inumab, data on effectiveness and safety was
also collected retrospectively from the start of
the treatment.
At enrolment, patient demographics and
clinical characteristics, medical and treatment
history were collected. Every prior biologic
treatment taken for PsO, PsA or AS was docu-
mented without a time limit; all other prior
PsO, PsA or AS treatments were only docu-
mented if taken within 6 months prior to
enrolment.
At enrolment, patients were assigned to the
indication of moderate to severe plaque PsO,
PsA or AS by the treating physician on the basis
of dominant indication intended for treatment
with secukinumab. This means that patients
having dominant PsO and treated by derma-
tologists are documented as patients with PsO;
and patients having dominant PsA or AS and
treated by rheumatologists are documented as
patients with PsA or AS, respectively. In addi-
tion, the dermatologists had a possibility to
document, at enrolment and during the study,
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if a patient with PsO has been diagnosed with
PsA. Depending on the documented diagnosis
(or diagnoses), different effectiveness and qual-
ity of life (QoL) parameters as listed below were
collected at enrolment and every 6 months for
up to 5 years.
• PsO PASI [65], body surface area (BSA, where
available) [66], Physician Global Assessment
(PGA) [65], psoriatic nail involvement
• PsA 78 Total Joint Count (TJC) and 76
Swollen Joint Count (SJC) including dactyli-
tis [67, 68], PGA [65], total pain visual
analogue scale (VAS) [69], enthesitis assess-
ment (Leeds Enthesitis Index, LEI) [70],
X-ray assessment, PASI (not routinely per-
formed by rheumatologists) [65], BSA (where
available), psoriatic nail involvement
• AS Bath AS Disease Activity Index (BASDAI)
[71], patient’s global assessment of disease
activity using numeric rating scale (NRS)
[27], C-reactive protein (CRP) and/or high-
sensitivity C-reactive protein (hsCRP) [72],
AS Disease Activity Score (ASDAS) [71], total
spinal pain VAS [73], enthesitis assessment
(Maastricht Ankylosing Spondylitis Enthesi-
tis Score, MASES) [74], X-ray and MRI assess-
ment of spine and/or sacroiliac joints
Data Analysis
The study was initiated in October 2016 and
enrolled over 2900 patients with moderate to
severe PsO, PsA or AS at 438 sites in 19 countries
across Europe until October 2018. This interim
analysis is mainly based on descriptive statisti-
cal methods; no imputations of data in analyses
were made. The following analysis sets were
used for statistical analysis and presentation of
data:
• Safety set: consists of patients who received
at least one dose of secukinumab treatment
after informed consent
• Full analysis set (FAS): consists of patients
who are included in the safety set and fulfil
all the inclusion criteria and none of the
exclusion criteria
The FAS is considered as the primary analysis
dataset and will be used for the primary and
additional variables. Baseline presentations
were based on the safety set and on the FAS. On
the basis of the dominant indication evaluated
at enrolment, patients were assigned to three
cohorts: PsO, PsA and AS. In the PsO cohort,
several parameters that are potential risk factors
for developing PsA, e.g. nail involvement or
joint involvement measured via presence of
dactylitis, were in addition analysed in the
subgroups of patients that did not report PsA at
enrolment and those that reported additional
diagnosis of PsA at enrolment. Previous treat-
ments of PsO, PsA and AS have been analysed as
previous medications taken prior to start of
secukinumab and also as treatment taken con-
comitantly to secukinumab for the given indi-
cation, i.e. PsO, PsA or AS. Patients could receive
more than one type of treatment (prior to start
of secukinumab or concomitant) e.g. combina-
tions of conventional systemic therapy with
topical treatments or non-steroidal anti-in-
flammatory drugs (NSAIDs), or biologics with
topical/NSAIDs and/or conventional systemic
agents. Every prior biologic treatment taken for
PsO, PsA or AS was to be documented without a
time limit, all other prior PsO, PsA or AS treat-
ments were to be documented only if taken
within 6 months prior to baseline visit.
In the prior treatment analyses, a patient was
assigned to the biologic pre-treated group if she/
he was treated with any biologic drug, irre-
spective of the original indication the medica-
tion was given for.
Comorbid medical condition and medical
history were coded using MedDRA and sum-
marized descriptively. Medical history events
that occurred after the first exposure to secuk-
inumab and prior to informed consent were
analysed for all safety events and for safety
events of special interest. Total exposure was
calculated as sum of all patient-years in each
subgroup, from first secukinumab treatment
date to informed consent date in this study.
Inflammatory bowel disease (IBD), major
adverse cardiovascular events (MACE) and
malignant tumours were identified using
Novartis MedDRA Queries (NMQs). Candida
infections were any events within the Candida
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infection MedDRA High Level Term; infections
were any events within MedDRA System Organ
Class Infections and Infestations. Hypersensi-
tivity and injection site reaction were identified
using Standard MedDRA Query (SMQ)
‘‘Hypersensitivity’’.
RESULTS
Disposition
Overall, 2932 patients were enrolled across
Europe (Supplementary Fig. 1) and 2800
patients were included in the safety set. Patients
(n = 132) who did not receive at least one
secukinumab injection after signing the
informed consent were excluded. On the basis
of the dominant indication evaluated at enrol-
ment, patients were assigned to three cohorts:
PsO (n = 1799), PsA (n = 541) and AS (n = 460).
A majority of the patients were treated with
secukinumab in non-clinical trial settings
except for 320 patients in the PsO cohort.
Demographics and Disease Characteristics
at Enrolment
Patients with PsA (N = 541) were older than
patients with PsO (N = 1799) and patients with
AS (N = 460); and patients with PsO and
patients with AS were predominantly male
(Table 1). At enrolment, 393 (21.8%) of patients
with PsO also reported PsA diagnosis. patients
with PsO had a higher mean body weight than
both PsA and patients with AS. The proportion
of obese patients (body mass index C 30 kg/m2)
was similar across indications, reported in a
total of 821 (37.2%) patients (Table 1). Time
since diagnosis was longer in patients with PsO
compared with PsA and patients with AS and
about 40% of all patients were either current or
former smokers.
Table 1 Demographics and clinical characteristics at enrolment
Characteristic PsO (N = 1799) PsA (N = 541) AS (N = 460)
Age (years), mean ± SDa 48.3 ± 13.6 52.4 ± 12.0 46.1 ± 11.5
Gender (male), n (%) 1209 (67.2) 241 (44.5) 270 (58.7)
Race (Caucasian), n (%) 1687 (93.8) 510 (94.4) 434 (94.3)
Body weight (kg), mean ± SD 87.2 ± 20.5 83.4 ± 18.0 80.1 ± 16.9
BMI (kg/m2), mean ± SD 28.7 ± 6.1 28.8 ± 5.7 27.0 ± 5.0
Overweight, 25 B BMI\ 30 (kg/m2), n (%) 361 (26.3) 126 (28.4) 146 (37.4)
Obesity, BMI C 30 (kg/m2), n (%) 519 (37.8) 163 (36.7) 139 (35.6)
Smoking status, n (%)b
Current 558 (31.0) 109 (20.2) 108 (23.5)
Former 242 (13.5) 85 (15.8) 63 (13.7)
Never 689 (38.3) 281 (52.1) 232 (50.4)
Time (years) since disease diagnosis, mean ± SD 17.4 ± 13.3 8.7 ± 7.9 9.3 ± 9.1
AS ankylosing spondylitis, BMI body mass index, N total number of patients in the study population, PsA psoriatic arthritis,
PsO psoriasis, SD standard deviation
a For patients whose age was missing and only year of birth was collected, age was calculated as date of baseline year of
birth - July 01
b Proportions do not add up to 100% as there were missing data or status was unknown for some patients
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Treatment Prior to Study Enrolment
Patients were treated with secukinumab for a
mean duration of 1 year prior to enrolment
(range 0.89–1.04 years, Table 2) and maximum
duration of 3.7–6.1 years across indications,
with a majority of patients treated for a period
between 16 weeks and 2 years (Fig. 2). Prior to
treatment with secukinumab, the proportions
of patients with PsO, PsA and AS who had
received biologic therapy for the respective
indications were 31.5%, 59.7% and 55%,
respectively (Fig. 3). Among patients with PsO,
the most frequently used biologic drug for the
treatment of PsO was adalimumab (58.6%),
followed by ustekinumab (44.3%), etanercept
(42.2%) and infliximab (21.3%, Supplementary
Fig. 2a). Among patients with PsA and patients
with AS, the most frequently used biologic was
adalimumab (56% and 51%), followed by
etanercept (45.8% and 46.6%), golimumab
(32.5% and 31.6%) and infliximab (30.3% and
28.9%, Supplementary Fig. 2b, c).
Among the 586 patients with PsO treated
with biologics for either PsO or PsA prior to
secukinumab, half (49.4%) of the patients were
treated with one biologic drug only (Fig. 4). A
quarter of the patients were treated with either
two (25.0%) or three and more biologics
(25.8%). Similar results were observed in
patients with AS. Previous treatment with one
biologic drug among patients with PsA was less
frequent (39.8%) compared to patients with PsO
and patients with AS. Compared to patients
with AS and patients with PsO, more patients
with PsA (34.7%) received secukinumab after
previous treatment with at least three biologics
drugs. Previous biologic treatment had been
discontinued for the majority of patients (range
81.7–90.6% across indications) as a result of lack
Fig. 2 Duration of secukinumab treatment prior to inclusion into SERENA study (na = 2794). na number of patients with
evaluation (i.e. with non-missing data); data includes also duration of secukinumab taken in clinical studies
Table 2 Secukinumab treatment duration prior to inclusion in the study
PsO (N = 1799) PsA (N = 541) AS (N = 460)
na 1793 538 455
Mean ± SD (years) 1.04 ± 0.64 0.99 ± 0.54 0.89 ± 0.50
Median (min, max) 0.92 (0.0, 6.1) 0.93 (0.0, 4.0) 0.77 (0.0, 3.7)
Data includes duration of secukinumab taken in clinical studies
na number of patients with evaluation (i.e. with non-missing data), N number of patients in the study population, SD
standard deviation
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of efficacy (Fig. 5). Prior to inclusion into the
study, most patients received secukinumab
alone (75% in PsO, 48.2% in PsA and 48.9% in
AS groups). In total, 19.3% of patients with PsO
were treated with topical treatments in addition
to secukinumab, and a small proportion
received additionally conventional systemic
treatments or phototherapy. Among patients
with PsA, 34.4% of patients received csDMARDs
in addition to secukinumab; 9.4% were treated
with NSAIDs. In total, 17.2% of patients with AS
were treated with csDMARDs and 27.8%
received NSAIDs as the only additional therapy
(Fig. 6). About one-fifth of the patients with PsO
and PsA had a family history of PsO mostly
involving first-degree relatives (FDRs, 19.1%
Fig. 4 Frequency of biologic pre-treated patients by number of previous therapies. na number of patients with evaluation
Fig. 3 Psoriasis treatment taken prior to start of secuk-
inumab treatment. Patients treated with conventional
systemic therapy could also have received topical treat-
ment/NSAIDs; patient treated with biologics could also
have received topical/NSAIDs and/or conventional treat-
ment. NSAIDs non-steroidal anti-inflammatory drugs,
csDMARDs conventional systemic disease-modifying anti-
rheumatic drugs
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and 17.6%, respectively). Similarly, about
17–20% of the patients with PsA and AS had a
family history of arthritis, mostly involving
FDRs (Fig. 7). Family history of other inflam-
matory diseases was less common with a fre-
quency of 10.9% in patients with AS.
Fig. 5 Frequency of patients by reason for discontinuation
of previous biologic treatment. na number of patients with
evaluation (i.e. biologic pre-treated); Patients could be
treated with more than one biologic drug prior to
secukinumab and may be counted in more than one group
Fig. 6 Psoriasis and AS treatment taken concomitantly to
secukinumab treatment. Patients treated with conventional
systemic therapy could also have received topical/NSAID
treatment, patient treated with biologics could also have
received topical /NSAID and/or conventional treatment.
Conv conventional, SEC secukinumab, NSAIDs non-
steroidal anti-inflammatory drugs, csDMARDs conven-
tional systemic disease-modifying antirheumatic drugs
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Disease Activity Status (at Start of Therapy
and at Study Enrolment)
The mean PASI score at the treatment start of
secukinumab was 20.7 ± 12.8 (n = 1605) and
7.6 ± 10.2 (n = 128) in PsO and PsA groups,
respectively. However, when the patients were
enrolled in SERENA, the mean PASI score was
3.0 ± 6.7 (n = 1648) and 2.0 ± 7.2 (n = 221),
respectively. Absolute PASI scores were low at
enrolment (at mean 1 year after therapy start)
with 45.8% of patients having PASI B 1 (Fig. 8).
Disease activity was measured at enrolment into
the study and is presented in Table 3. In total,
Fig. 7 Familial history of inflammatory diseases. A first-
degree relative is defined as a close blood relative which
includes the individual’s parents, full siblings or children. A
second-degree relative is defined as a blood relative which
includes the individual’s grandparents, grandchildren,
aunts, uncles, nephews, nieces or half-siblings
Fig. 8 Percentage of patients by absolute PASI score category at enrolment. PASI Psoriasis Area and Severity Index
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71.8% of patients with PsO and 61.1% of
patients with PsA reported PGA 0/1 (clear or
almost clear skin) at enrolment. Among
patients with PsA, 54.7% presented with joint
involvement (any joint tender or swollen) with
a mean (SD) number of tender 6.4 (9.5) and
swollen joints 3.3 (5.8). About one-fifth (19%)
of the patients with PsA had enthesitis (LEI,
mean (SD) 0.4 [1.1]) at enrolment. Overall,
21.6% of patients with PsO without PsA at
enrolment, 32.4% of patients with PsO and PsA
at enrolment and 17.8% of patients with PsA
had nail involvement, respectively. Overall,
0.6% of patients with PsO without formally
diagnosed PsA at enrolment, 6.9% of patients
with PsO and PsA at enrolment and 6.6% of
patients with PsA had dactylitis, respectively.
Patients with AS at enrolment had mean (SD)
ASDAS-CRP score of 2.3 (0.9) and BASDAI score
of 3.3 (2.3). A proportion of patients with AS
had achieved ASDAS-CRP inactive disease status
(15.4%) or low disease activity (31.6%) at the
time of enrolment (Supplementary Fig. 3). In
total, 26% of patients with AS had enthesitis
(MASES) with a mean (SD) enthesitis index of
0.7 (1.7). The mean (SD) Patient’s Global
Assessment of AS (VAS 10 cm) and total back
pain (VAS 100 mm) scores were 4.2 (3.2) and
34.9 (24.2), respectively. In the overall AS pop-
ulation, mean (SD) CRP was 8.8 (14.1) mg/L at
enrolment; more than a half of patients with AS
(58.5%) had normal CRP (B 5 mg/mL) levels
(overall median of 4 mg/L).
Safety
The cumulative exposure to secukinumab
treatment prior to enrolment was 2809.8 pa-
tient-years. There were low rates of retrospective
reporting of events of special interest. The per-
centage of patients reporting any infection was
Table 3 Disease activity status at enrolment
Characteristic PsO (N = 1799) PsA (N = 541) AS (N = 460)
PGA response 0/1 (clear/almost clear skin), n/M (%) 531/740 (71.8%) 192/314 (61.1%) –
Tender joint count, mean ± SD (M) – 6.4 ± 9.5 (211) –
Swollen joint count, mean ± SD (M) – 3.3 ± 5.8 (212) –
Absence of tender or swollen joint, n/M (%) – 236/521 (45.3%) –
HAQ-DI Score, mean ± SD (M) 0.50 ± 0.57 (26) 0.83 ± 0.71 (404) 0.81 ± 0.70 (430)
ASDAS-CRP, mean ± SD (M) – – 2.3 ± 0.9 (234)
Enthesitis index, mean ± SD (M) – 0.4 ± 1.1a (275) 0.7 ± 1.7b (243)
Pain (VAS 0–100 mm), mean ± SD (M) – 31.9 ± 24.2c (440) 34.9 ± 24.2d (349)
BASDAI, mean ± SD (M) – – 3.3 ± 2.3 (423)
PtGA of AS (VAS 0–10 cm), mean ± SD (M) – – 4.2 ± 2.3 (360)
CRP (mg/L), mean ± SD (M) – – 8.8 ± 14.1 (287)
AS ankylosing spondylitis, ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis
Disease Activity Index, CRP C-reactive protein, M number of patients with evaluation, n number of patients with a
response, N number of patients in the study population, PGA Physician’s Global Assessment, PsA psoriatic arthritis, PsO
psoriasis, PtGA Patient’s Global Assessment, SD standard deviation, VAS visual analogue scale
a Leeds enthesitis index
b Maastricht Ankylosing Spondylitis Enthesitis Score
c Total pain
d Total back pain
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3.3%. Higher rates of patients reporting any
infection were observed among patients with
PsO (4.0%) than among patients with PsA
(1.8%) or patients with AS (2.4%). Overall, two
cases (0.07%) of IBD were reported (one each in
PsA and AS cohort), both of which were new-
onset. No unexpected safety signals were
reported (Table 4).
DISCUSSION
SERENA is the first study to investigate secuk-
inumab use in everyday clinical practice in
Europe across all three therapeutic indications:
moderate to severe plaque PsO, active PsA and
active AS. In addition, SERENA includes patients
with potential comorbidities, prior or con-
comitant medications that may have led to
their exclusion from randomized controlled
trials (RCTs). Furthermore, non-interventional
studies provide complementary evidence to
RCTs, comparative effectiveness with other
treatments that can inform payers and clini-
cians and may result in hypothesis generation
[50, 56]. Finally, SERENA will collect long-term
retention (primary endpoint) and safety out-
comes in broad populations treated in routine
clinical practice.
The demographics in SERENA are consistent
with other interventional trials with
secukinumab in PsO, PsA and AS
[43, 54, 55, 57, 58], and other real-world studies
[59, 60].
However, in terms of baseline disease char-
acteristics, the time since diagnosis of AS was
longer in SERENA with a mean duration of
9.3 years as opposed to RCTs ranging from 5.3
to 8.3 years. Furthermore, disease activity at
enrolment was generally less severe than those
reported at baseline in phase 3 clinical trials
because the majority of the patients included in
the SERENA study received secukinumab treat-
ment for a period between 16 weeks and 2 years
with a mean duration of 1 year (range 0.89–-
1.04 years) prior to enrolment [46–48, 75–79].
In contrast to phase 3 secukinumab trials
[46–48], most patients enrolled in SERENA were
treated with other biologics (mostly anti-TNFs)
prior to receiving secukinumab. Notably, more
than one-quarter of these patients received
three or more biologics prior to secukinumab.
Among all three cohorts, lack of efficacy was the
major reason for discontinuation and hence
effectiveness data should be interpreted by tak-
ing into consideration that previous treatments
had not adequately controlled disease symp-
toms. These results are similar to findings from
two large non-interventional studies in Ger-
many, AQUILA (secukinumab use in patients
with active AS or PsA) [60] and PROSPECT
Table 4 Medical history: patients reporting events of special interest occurring prior to enrolment during the secukinumab
treatment
PsO (N = 1799) PsA (N = 541) AS (N = 460) Total (N = 2800)
Total exposure (patient-years) 1870.9 533.1 405.8 2809.8
Candida infections, n (%) 12 (0.7) – – 12 (0.43)
Malignancy, n (%) 9 (0.5) 2 (0.4) 1 (0.2) 12 (0.43)
Major adverse cardiovascular events, n (%) 1 (0.1) – – 1 (0.04)
Inflammatory bowel disease, n (%) – 1 (0.2) 1 (0.2) 2 (0.07)
Injection site reactions, n (%) 1 (0.1) – – 1 (0.04)
Infectionsa, n (%) 72 (4.0) 10 (1.8) 11 (2.4) 93 (3.3)
Only events occurred during the exposure to secukinumab are reported
n number of patients with an event, % percentage of patients with an event
a Including Candida infections
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(secukinumab use in patients with active mod-
erate to severe PsO) [61]. The US Psoriasis Reg-
istry CORRONA also reports comparable
conclusions [80–82].
Safety data presented here are related to
events that occurred during the exposure to
secukinumab preceding the enrolment to the
study. As a result of the retrospective character
of safety data collection, some of the safety
events, especially those of mild nature, might
not be reported. Nevertheless, no new safety
signals were identified within the analysis of
available data. Further analyses of safety events
observed during the study will provide further
valuable information into safety aspects of
secukinumab use in the real world.
The limitations of this study result from its
observational nature including absence of con-
trol group, incomplete data and selection bias.
For example, some baseline characteristics such
as the use of prior medications other than bio-
logics were not collected if exposure occurred
more than 6 months prior to enrolment. Selec-
tion bias was inevitably introduced as patients
had to be treated for at least 16 weeks with
secukinumab prior to enrolment as the main
objective of this study is to focus on the long-
term drug retention and safety rather than ini-
tial effectiveness of secukinumab treatment.
Efficacy achieved within 16 weeks of treatment
is already well proven in the clinical develop-
ment program of secukinumab. Furthermore,
SERENA was conducted in 19 countries in Eur-
ope only, and findings cannot be generalized to
all patients with PsO, PsA and AS worldwide. In
addition, there was an imbalance between the
number of patients enrolled in countries. Since
the data have been collected retrospectively for
up to 6 years for some individuals, underre-
porting of prior medications and more impor-
tantly of adverse events cannot be excluded. All
limitations have descriptive character only,
with no adjustments made to control for
potential confounding variables.
CONCLUSIONS
In terms of demographics, the SERENA popula-
tion is consistent with other interventional
trials with secukinumab; however, there are
some significant differences pertinent to the
baseline disease characteristics. Patients enrol-
led in SERENA had prior exposure to multiple
biologics, mostly TNF inhibitors, and relatively
lower disease activity compared to phase 3
studies as they were already treated with
secukinumab for a period between 16 weeks and
2 years.
This large observational study across all three
secukinumab indications will provide further
information on the long-term effectiveness and
safety of secukinumab in the real-world setting.
Full effectiveness and safety results will be
reported in a future publication.
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